BriaCell Therapeutics Corp. (BCTX)
NASDAQ: BCTX · Real-Time Price · USD
4.180
+0.010 (0.24%)
At close: Feb 6, 2026, 4:00 PM EST
4.150
-0.030 (-0.72%)
After-hours: Feb 6, 2026, 7:24 PM EST
BriaCell Therapeutics Employees
BriaCell Therapeutics had 16 employees as of July 31, 2023. The number of employees increased by 10 or 166.67% compared to the previous year.
Employees
16
Change
10
Growth
166.67%
Revenue / Employee
n/a
Profits / Employee
-$1,794,204
Market Cap
25.95M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jul 31, 2023 | 16 | 10 | 166.67% | 16 | 0 |
| Jul 31, 2021 | 6 | 0 | - | 5 | 1 |
| Aug 1, 2019 | 6 | - | - | 5 | 1 |
Related Stocks
| Company Name | Employees |
|---|---|
| Barinthus Biotherapeutics | 105 |
| IGC Pharma | 70 |
| Evaxion | 46 |
| Cue Biopharma | 41 |
| Palatin Technologies | 29 |
| TuHURA Biosciences | 19 |
| NeuroSense Therapeutics | 17 |
| Skye Bioscience | 16 |
BCTX News
- 9 days ago - BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation - GlobeNewsWire
- 10 days ago - BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients - GlobeNewsWire
- 22 days ago - BriaCell Therapeutics Announces Closing of US$30 million Public Offering - GlobeNewsWire
- 24 days ago - BriaCell Therapeutics Announces Pricing of $30 million Public Offering - GlobeNewsWire
- 24 days ago - BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient - GlobeNewsWire
- 7 weeks ago - “Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine - GlobeNewsWire
- 2 months ago - BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025 - GlobeNewsWire
- 2 months ago - BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout - GlobeNewsWire